Genentech Cathflo Activase is approved
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA clears tissue plasminogen activator alteplase Sept. 4 for restoring function to occluded central venous access catheters. Genentech's Cathflo Activase will be sold in 2 mg single-use vials, while Activase, indicated for acute MI, acute ischemic stroke and acute massive pulmonary embolism, is sold in 50 and 100 mg vials (Pharmaceutical Approvals Monthly, February 2001, p. 18). The only other product approved for clearing occluded catheters is Abbott's Abbokinase (urokinase), which was pulled from the market in 1999 for GMP deficiencies. Abbott anticipates re-launching its drug in first quarter 2002
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.